TAMRA OGILVIE to Medulloblastoma
This is a "connection" page, showing publications TAMRA OGILVIE has written about Medulloblastoma.
Connection Strength
2.289
-
From sorting to sequencing in the molecular era: the evolution of the cancer stem cell model in medulloblastoma. FEBS J. 2022 04; 289(7):1765-1778.
Score: 0.490
-
A group 3 medulloblastoma stem cell program is maintained by OTX2-mediated alternative splicing. Nat Cell Biol. 2024 08; 26(8):1233-1246.
Score: 0.308
-
Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma. Nat Commun. 2023 05 02; 14(1):2502.
Score: 0.284
-
Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression. Commun Biol. 2022 07 14; 5(1):697.
Score: 0.268
-
An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. Nat Commun. 2020 07 20; 11(1):3627.
Score: 0.234
-
CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma. Cancer Res. 2018 08 15; 78(16):4745-4759.
Score: 0.202
-
Characterization of a novel OTX2-driven stem cell program in Group 3 and Group 4 medulloblastoma. Mol Oncol. 2018 04; 12(4):495-513.
Score: 0.198
-
Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes. Oncotarget. 2015 Nov 17; 6(36):38881-900.
Score: 0.169
-
Failure of human rhombic lip differentiation underlies medulloblastoma formation. Nature. 2022 09; 609(7929):1021-1028.
Score: 0.136